In exploring the mechanisms of this allogeneic CD4+ T cell help in tumor challenge studies, we discovered that this help was induced only at an early stage of tumor growth by the peptide-pulsed MHC class II semiallogeneic DC vaccine. The gene discussed is CD4; the disease is neoplasm.